Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 48.07% | -312.97% | 499.74% | -88.48% | 513.90% |
| Total Depreciation and Amortization | -40.38% | -3.70% | -3.57% | 5.66% | -1.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.04% | 215.63% | -283.78% | 82.99% | -2,288.26% |
| Change in Net Operating Assets | -99.08% | -25.34% | 448.56% | -38.50% | -124.86% |
| Cash from Operations | 73.09% | -442.05% | 240.65% | -4.09% | -104.32% |
| Capital Expenditure | -120.00% | -- | 100.00% | 33.33% | 90.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.06% | -136.19% | 215.52% | 0.00% | 139.95% |
| Cash from Investing | 145.02% | -136.19% | 215.54% | 0.00% | 139.93% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | 100.00% | -60.79% | 24.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 7.44% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.44% | 95.77% | -60.79% | 24.00% | -133.54% |
| Foreign Exchange rate Adjustments | -166.67% | 175.00% | -300.00% | -112.50% | 125.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.88% | -164.45% | 595.06% | 165.43% | 376.14% |